Triple Versus Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation

NCT00404716 | Completed Phase 4

• 1 other identifier: NH-2006-A006
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Cilostazol is an kind of oral antiplatelet agent with a rapid onset of action that selectively inhibits phosphodiesterase III, a mechanism different from adenosine diphosphate (ADP) receptor antagonists. Previous studies had suggested that cilostazol has lipid-modifying and vasodilating effects in addition to antiplatelet effects. From those experimental and clinical backgrounds, we assumed that triple antiplatelet therapy with aspirin, clopidogrel, and cilostazol might have a beneficial effect on the prevention of atherothrombosis complications following coronary stenting. Therefore, we evaluated the safety and efficacy of triple antiplatelet regimen of aspirin, clopidogrel and cilostazol compared with dual antiplatelet regimen of aspirin and clopidogrel in patients with acute coronary syndrome undergoing successful coronary artery stenting. Patients undergoing successful coronary stenting were divided into dual antiplatelet therapy (aspirin plus clopidogrel) and triple antiplatelet therapy (aspirin and clopidogrel plus cilostazol) groups. All enrolled patients in triple regimen group will receive cilostazol 100mg, b.i.d., for 6 months in addition to standard dose and duration of aspirin and clopidogrel for post-PCI. The primary endpoints included death, myocardial infarction, target lesion revascularization, stent thrombosis within 30 days, binary restenosis at six month and major adverse cardiac events (MACE) at one year. The secondary endpoints were side effects of study drugs, including major bleeding, vascular complication, hypersensitivebility, and bleeding complications. The study will be powered to test the hypothesis that triple antiplatelet therapy is better than dual antiplatelet therapy.

Conditions

Acute Coronary Syndrome

Interventions

Cilostazol DRUG

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosed with ACS Undergoing coronary stent implantation
• Between ages of above 18 Years and bellow 80 Years.
• Presence of one or several stenosis in native coronary arteries requiring PCI.
• Willing and able to sign informed consent.

You may not qualify if:

• A history of bleeding diathesis.
• New York Heart Association functional class IV.
• Prior PCI or coronary bypass grafting \< 3 months.
• Contraindications to clopidogrel and aspirin (White blood cells counts \< 4×109/L or platelet counts \<100 g.l-1 ;creatinine clearance \<25 ml • min-1 ;active liver disease).
• Use of glycoprotein IIb/IIIa inhibitors before PCI.
• Preparing to undergo CABG
• Taken clopidogrel or cilostazol recently

Sponsors & Collaborators

• Shenyang Northern Hospital: lead

MeSH Terms

Conditions

Acute Coronary Syndrome

Interventions

Cilostazol

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases

Intervention Hierarchy (Ancestors)

Tetrazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Quinolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Officials

• Yaling Han, Dr.

  Shenyang Northern Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: November 28, 2006
• First Posted: November 29, 2006
• Study Start: December 1, 2004
• Study Completion: February 1, 2007
• Last Updated: November 29, 2006

Record last verified: 2006-11